Dr. Paolo Mignatti
Contact:
Department of Cardiothoracic Surgery,
NYU School of Medicine - - ------NB-15W16, 28th Street & First Avenue New York, NY 10016 USA
Tel. (212) 263-1478
E-mail: mignap01@med.nyu.edu
Education |
|
|
|
University |
Degree |
Year |
Field |
University of Pavia (Italy) School of Medicine |
M.D. |
1975 |
Medicine |
University of Pavia (Italy) School of Medicine |
Specialty |
1978 |
Hematology-Oncology |
Pasteur Institute, Paris (France) |
Diploma |
1980 |
General Immunology |
Postdoctoral Training
1976-1978 Genetics and Hematology Institute of Genetics an
1984 -1985 Cell Biology NYU School of Medicine,Dept. of Cell Biology
Licensure and Certification1975 - Italian Medical Association Academic Appointments
Associate Professor of NYU School of Medicine, Surgical Research and Cell Biology - Depts. of Surgery and Cell Biology Member of the Faculty of the NYU School of Medicine Sackler Institute of Graduate Biomedical Studies
Member of the NYU Cancer Center NYU School of Medicine
Other Professional Positions and Visiting Appointments
1995 -1996, American Cancer Society Fellow - NYU School of Medicine Dept. of Cell Biolog
Memberships
1975 - present, Italian Medical Association, Member
1996 - present, American Society for Cell Biology, Member
Research Interests
Molecular and Cellular Mechanisms of Intimal Hyperplasia
This project aims to investigate the mechanisms that control the generation of intimal hyperplasia in arterialized vein grafts or injured arteries. The investigation focuses on the role of intracellular signaling pathways activated in vascular cells following vein grafting or arterial injury and their control of medial cell proliferation and migration, the proteolytic activities and inflammatory mediators that contribute to this process. The ultimate goal of the project is to provide indications for the development of systemic or topical pharmacological treatments to prevent vascular restenosis.
Growth Factor Interactions in Angiogenesis
The aim of this project is to investigate autocrine mechanisms of angiogenesis mediated by transforming growth factor-beta 1 (TGF-b1), fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). The project studies the role of interactions between these growth factors in the control of endothelial cell functions involved in angiogenesis in vitro and in vivo. The results of these experiments can be exploited for the development of pharmacological tools aimed either at inhibiting angiogenesis during tumor growth or stimulating it in chronically ischemic tissues.
Signaling via Membrane-Type 1 Matrix Metalloprotease
This project investigates the molecular and cellular mechanisms of signal transduction generated by the cell surface interaction between membrane-type 1 matrix metalloproteinase (MT1-MMP) and its physiological inhibitor, the tissue inhibitor of metalloproteinases-2 (TIMP-2), and its effect on tumor cell proliferation and migration in vitro and in vivo. Understanding these mechanisms can afford the development of pharmacological treatments aimed to control tumor growth and metastasis as well as physiological and pathological processes that involve cell proliferation and migration.
Galloway AC, Mignatti P, Pintucci G. Inhibition of Mitogen Activated Protein Kinases in Cardiovascular Disease. United States Patent 05986/1200886-US1, filed August 2005. This invention relates to the use of synthetic inhibitors of mitogen-activated protein kinases for treating or preventing hyperproliferative vascular disease, including intimal hyperplasia of venous, arterial or synthetic bypass grafts, restenosis of native coronary arteries or pheripheral vessels after angioplasty or vascular stenting, and vascular restenosis or occlusion after localized injury or intervention.
Teaching
Lectures in:
Pharmacology program, NYU Sackler Institute of Graduate Biomedical Studies.
Environmental Carcinogenesis course, NYU Graduate School of Biological Sciences.
Cell Biology and Anatomy course, NYU School of Medicine.
Clinical Pharmacology Grand Rounds
Basic Science lectures for Surgery residents, NYU School of Medicine.
Dermatology Grand Rounds, NYU School of Medicine.
Pulmonology Grand Rounds
Invited lecturer at numerous universities and research centers in US and Europe, including:
Brigham and Women’s Hospital, Harvard University, Boston
Yale University School of Medicine
Cornell University School of Medicine, New York
Mount Sinai School of Medicine, New York
National Cancer Institute, Bethesda
University of Copenhagen School of Medicine, Denmark
University of Helsinki School of Medicine, Finland
University of Geneva School of Medicine, Switzerland
University of Vienna School of Medicine, Austria
University of Toulouse School of Medicine, France
Invited speaker at numerous international conferences, including:
Gordon Research Conference on Proteolysis
Gordon Research Conference on Matrix Metalloproteinases
American Association for Cancer Research
European Association for Cancer Research
International Society for Fibrinolysis and Proteolysis
Editorship:
2004 – 2005, Section Editor, Thrombosis & HaemostasisEditorial Boards
1995 - 2000 Associate Editor, Invasion and Metastasis
Ad Hoc Reviewer for:
1989 – present - American Journal of Pathology, Arteriosclerosis, Thrombosis and Vascular Biology, Blood, British Journal of Cancer, Cancer Research, Clinical & Experimental Metastasis, Clinical Cancer Research, EMBO Journal, Experimental Cell Research, FASEB Journal, International Journal of Cancer, Journal of Biological Chemistry, Journal of Cell Biology,Journal of Cell Biochemistry, Journal of Cellular Physiology, Journal of Cell Science, Laboratory Investigation, Microcirculation, Oncology, Thrombosis & Haemostasis, Thrombosis Research
Major Committee Assignments
1989 – 2003, Member of the International Scientific Committee of the International Workshops on the Molecular and Cellular Biology of Plasminogen Activation
1996 - present, Ad hoc reviewer of grant applications for the British Medical Research Council, the Dutch Cancer Society, the Swiss Cancer Society and the Italian Association for Cancer Research
2000 – 2004, Ad hoc reviewer for NIH National Heart, Blood and Lung Institute and National Cancer Institute study sections
2000 – present, Member of the Cardiovascular Biology Subcommittee of the NYU School of Medicine Dean’s Advisory Committee
2001, Member of the International Organizing Committee of the First Chianti Meeting on Proteases (Pontignano, Siena, Italy)
2001, Member of the International Organizing Committee of the International Congress on Membrane-Bound Proteolytic Enzymes and Cancer (Palermo, Italy)
2001 – present, Member of the NYU School of Medicine Gene Therapy Group
2003, Member of the ad hoc Committee for the Periodic Review of the Department of Environmental Medicine, NYU School of Medicine
2004 - present, Member of the Cardiovascular Biology Search Committee for the recruitment of new faculty to work in the field of cardiovascular biology
2004, Member of the International Organizing Committee of the Second Chianti Meeting on Proteases (Pontignano, Siena, Italy)
2004-2006, Ad hoc reviewer for the Atherosclerosis, Inflammation and Cardiovascular Sciences (AICS) Study Section, NIH
2005 – present, Reviewer for Italian Association for Cancer Research (AIRC) grant applications
2005 – present, Reviewer for American Association for the Advancement of Science (AAAS) grant applications
Publications
Original Reports
1.Barlati S, Mignatti P, Krycève C, Vigier P. Properties and kinetics of development of Rous sarcoma virus-infected cells evidenced by methylene blue staining. Intervirology 1975-76; 6: 25-31.
2.Mignatti P, Ascari E, Barlati S. Potential diagnostic and prognostic significance of the transformation-enhancing factor(s) in the plasma cryoprecipitate of tumor patients. International Journal of Cancer 1980; 25: 727-734.
3.De Petro G, Brega A, Mignatti P, Barlati S. Inhibition of Rous sarcoma virus-induced transformation by proteins involved in blood coagulation. International Journal of Cancer 1980; 25: 557-560.
4.Krycève-Martinerie C, Biquard JM, Lawrence D, Vigier P, Barlati S, Mignatti P. Transformation-enhancing factor(s) released from Rous sarcoma cells: effect on some transformation parameters. Virology 1980; 112: 436-449.
5.Mignatti P, Barlati S. Enhancement of plasminogen activator activity by the culture medium of Rous sarcoma virus-transformed cells. Journal of General Virology 1982; 63: 365-373.
6.Mignatti P, Pagani L, Romero E. A plasmid-linked caseinolytic activity in Enterobacteriaceae. Microbiologica 1983; 6: 229-237.
7.Mignatti P. A method for evaluating the statistical accuracy of in vitro virus titrations. Microbiologica 1983; 6: 55-68.
8.Romero E, Pagani L, Perduca M, Mignatti P, Malfa S, Mills V. Relationship between ß-lactamase production and resistance to ß-lactam antibiotics in clinical isolates of Enterobacteriaceae. Microbiologica 1984; 7: 209-217.
9.Cereda PM, Debiaggi M, Mignatti P, Pagani L, Romero E. Bovine leukemia virus-inhibiting activity in fetal calf serum. Microbiologica 1984; 7: 251-255.
10.Saksela O, Vaheri A, Schleuning WD, Mignatti P, Barlati S. Plasminogen activators, activation inhibitors and alpha 2-macroglobulin produced by cultured normal and malignant human cells.International Journal of Cancer 1984; 33: 609-616.
11.Mignatti P, Speziale P, Pagani L, Romero E. Degradation of human fibronectin by strains of E. coli K12 carrying R factors from Klebsiella pneumoniae. Microbiologica 1985; 8: 67-71.
12.Presta M, Mignatti P, Mullins DE, Moscatelli D. Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production. Bioscience Reports 1985; 5: 783-790.
13.Moscatelli D, Presta M, Mignatti P, Mullins DE, Crowe RM, Rifkin D.B. Purification and biological activities of an angiogenesis factor from human placenta. Anticancer Research 1986; 6: 861-864.
14.Mignatti P, Robbins E, Rifkin D.B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 1986; 47: 487-498.
15.Barlati S, Colombi M, Mignatti P. Plasminogen activator activity of human plasma and transformed cells conditioned media: dependence on divalent cations. Fibrinolysis 1987; 1: 189-194.
16.Barlati S, De Petro G, Colombi M, Rebessi L, Adamoli A, Brega A, Mignatti P. Transformation-enhancing factors in vitro and in vivo: potential as cancer markers. The Cancer Journal 1988; 2: 95-104.
17.De Petro G, Mignatti P, Vartio T, Vaheri A, Barlati S. Neutralization of transformation-enhancing activity by anti-fibronectin monoclonal antibodies. The Cancer Journal 1989; 3: 107-115.
18.Rifkin DB, Tsuboi R, Mignatti P. The role of proteases in matrix breakdown during cellular invasion. American Review of Respiratory Disesases 1989; 140: 1112-1113.
19.Mignatti P, Tsuboi R, Robbins E, Rifkin DB. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. The Journal of Cell Biology 1989; 108: 671-682.
20.Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc. Natl. Acad. Sci. USA 1991; 88: 11007-11011.
21.Mignatti P, Rifkin D.B. Release of basic fibroblast growth factor, an angiogenic factor devoid of secretory signal sequence: a trivial phenomenon or a novel secretion mechanism? Journal of Cellular Biochemistry 1991; 47: 201-207.
22.Rifkin DB, Moscatelli D, Bizik J, Quarto N, Blei F, Dennis P, Flaumenhaft R, Mignatti P. Growth factor control of extracellular proteolysis. Cell Differentiation and Development 1991; 32: 313-318.
23.Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. The Journal of Cell Biology 1991; 113: 1193-1201.
24.Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. Journal of Cellular Physiology 1992; 151: 81-93.
25.Vagnarelli P, Raimondi E, Mazzieri R, De Carli L, Mignatti P. Assignment of the human urokinase receptor (PLAUR) gene to 19q13. Cytogenetics and Cell Genetics 1992; 60: 197-199.
26.Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor ß in endothelial cells: regulation of plasminogen activator activity. The Journal of Cell Biology 1992; 118: 901-909.
27.Blei F, Wilson EL, Mignatti P, Rifkin D.B. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. Journal of Cellular Physiology 1993; 155: 568-578.
28.Masiero L, Mazzieri R, Kalebic T, Mignatti P, Garbisa S. Modulation of expression and activity of MMP-2 by reducing agents and uPA-plasmin. European Journal of Histochemistry 1993; 37: 60-61.
29.Mazzieri R, Høyer-Hansen G, Rønne E, Løber D, Vagnarelli P, Raimondi E, De Carli L, Danø K, Mignatti P. Urokinase and urokinase receptor expression in somatic cell hybrids. Fibrinolysis 1994; 8: 344-352.
30.Peverali FA, Mandriota S, Ciana P, Marelli R, Quax P, Rifkin DB., Della Valle G, Mignatti P. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. Journal of Cellular Physiology 1994; 161: 1-14.
31.Mandriota S, Seghezzi G, Mazzieri R, Vassalli JD, Ferrara N, Wasi S, Orci L, Montesano R, Mignatti P, Pepper M.S. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. Journal of Biological Chemistry 1995; 270: 9709-9716.
32.Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin D.B. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. The Journal of Cell Biology 1995; 129: 233-243.
33.Seghezzi G, Marelli R, Mandriota SJ, Nolli ML, Mazzieri R, Mignatti P. Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells. Journal of Cellular Physiology 1996; 169: 300-308.
34.Mazzieri R, Masiero L, Zanetta L, Onisto M, Garbisa S, Mignatti P. Control of type IV collagenase activity by components of the urokinase - plasmin system: a regulatory mechanism with cell-bound reactants. The EMBO (European Molecular Biology Organization) Journal 1997; 16: 2319-2332.
35.Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, Vittorelli M.L. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. The Journal of Biological Chemistry 1997, 272: 17216-17222.
36.Schwartz JD, Monea S, Marcus SG, Patel S, Eng K, Galloway AC, Mignatti P, Shamamian P. Soluble factor(s) released from neutrophils activates endothelial cell matrix metalloproteinase-2. Journal of Surgical Research 1998, 76: 79-85.
37.Schwartz JD, Shamamian P, Monea S, Whiting D, Marcus SG, Galloway AC, Mignatti P. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase. Surgery 1998, 124: (2) 232-238.
38.Fernandez H, Kallenbach K, Seghezzi G, Mehrara B, Apazidis A, BaumannG, Grossi E, Colvin S, Mignatti P, Galloway AC. Modulation of matrix metalloproteinase (MMP) activity in human saphenous vein grafts (hSVG) using adenovirus-mediated gene transfer. Surgery 1998, 124: 129-136.
39.Ren CJ, Ueda F, Roses DF, Harris MN, Mignatti P, Rifkin DB, Shapiro RL. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice. Journal of Surgical Research1998, 77:126-131.
40.Seghezzi G, Patel S Ren CJ, Pintucci G, Gualandris A, Robbins RL, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism of angiogenesis. The Journal of Cell Biology 1998, 141: 1659-1673.
41.Fernandez H, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R., Mignatti P, Galloway AC. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of matrix metalloproteinases-1. Journal of Surgical Research 1999, 82: 156-162.
42.Zanetta L., Marcus S.G., Vasile J., Dobryansky M., Cohen H., Eng K., Shamamian P., and Mignatti P. Expression of von Willebrand factor, an endothelial cell marker, is upregulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. International Journal of Cancer 2000, 85: 281-288.
43.Shamamian P., Pocock B.J.Z., Schwartz J.D., Monea S., Chuang N., Whiting D., Marcus S., Galloway A.C., Mignatti P. Neutrophil-derived proteinases (NDP) enhance membrane-type 1 matrix metalloproteinase (MT1-MMP)-dependent tumor cell invasion. Surgery 2000, 127:142-147.
44.Liao, F., Li, Y., O’Connor, W., Zanetta, L., Bassi, R., Santiago, A., Overholser, J., Hooper, A., Mignatti, P., Dejana, E., Hicklin, D.J., Bohlen, P. Monoclonal Antibody to Vascular Endothelial (VE)-cadherin Is a Potent Inhibitor of Angiogenesis, Tumor Growth and Metastasis. Cancer Research 2000, 60: 6805-6810.
45. Shamamian P., Schwartz J.D., Pocock B.J.Z., Monea S., Whiting D., Marcus S.G., Mignatti P. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin g and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. Journal of Cellular Physiology 2001, 189: 197-206.
46.Pintucci G., Moscatelli D., Saponara F., Biernacki P.R., Baumann F.G., Bezekis C., Galloway A.C., Basilico C., and Mignatti P. Lack of ERK Activation and Cell Migration in FGF-2-Deficient Endothelial Cells. FASEB Journal2002, 10.1096/fj.01-.0815fje.
47. Hyman KM, Seghezzi G, Pintucci G, Stellari G, Kim JH, Grossi E A, Galloway, AC, Mignatti P. Transforming growth factor-beta1 induces apoptosis in vascular endothelial cells via activation of mitogen-activated protein kinase. Surgery 2002, 132:173-179
48.Monea M, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase dependent mechanism. Journal of Cellular Physiology 2002, 192:160-170.
49. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti P, Shamamian P. Increased membrane type 1 matrix metalloproteinase expression from adenoma to colon cancer: a possible mechanism of neoplastic progression. Dis. Colon Rectum 2002, 45:537-543.
50.Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, Green D. Trophic Effects of Platelets on Cultured Endothelial Cells are Mediated by Platelet-associated Fibroblast Growth Factor-2 (FGF-2) and Vascular Endothelial Growth Factor (VEGF). Thromb. Haemost. 2002, 88:834-842.
51. Kallenbach K, Fernandez H, Baumann FG, Seghezzi G, Patel S, Grossi EA, Galloway AC, Mignatti P. An in vitro model of smooth muscle cells migration through the arterial wall using the human amniotic membrane: a novel quantitative method to study vascular remodeling. Arteriosclerosis, Thrombosis and Vascular Biology 2003, 23:1008-1013.
52. Bizekis C, Pintucci G, Derivaux CC, Saponara F, Kim J-H, Hyman KM, Grossi EA, Baumann FG, Mignatti P, Galloway AC. Activation of mitogen-activated protein kinases during preparation of vein grafts and modulation by a synthetic inhibitor. The Journal of Thoracic and Cardiovascular Surgery 2003, 126: 659-665.
53. Pintucci G, Yu P-J, Sharony R, Baumann FG, Saponara F, Frasca A, Galloway AC, Moscatelli D, Mignatti P. Induction of stromelysin-1 (MMP-3) by fibroblast growth factor-2 (FGF-2) in FGF-2 -/- microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2). Journal of Cellular Biochemistry 2003, 90: 1015-1025.
54. Taverna S, Ghersi G, Ginestra A, Rigogliuso S, Pecorella S, Alaimo G, Saladino F, Dolo V, Dell'Era P, Pavan A, Pizzolanti G, Mignatti P, Presta M, Vittorelli ML. Shedding of Membrane Vesicles Mediates Fibroblast Growth Factor-2 Release from Cells. J. Biol. Chem. 2003, 278: 51911 - 51919.
55. Saunders PC, Pintucci G, Bizekis CS, Sharony R, Hyman KM, Saponara F, Baumann FG, Grossi EA, Colvin SB, Mignatti P, Galloway AC. Vein graft arterialization causes differential activation of mitogen-activated protein kinases. Journal of Thoracic and Cardiovascular Surgery 2004, 127: 1276 1284.
56. Pintucci G., Yu P.-J., Saponara F., Kadian-Dodov D., Galloway A., Mignatti P. PDGF-BB induces vascular smooth muscle cell expression of high molecular weight FGF-2, which accumulates in the nucleus. Journal of Cellular Biochemistry 2005, 95: 1292-1300.
57.Gulkarov I, Pintucci G, Bohmann K, Saunders PC, Sullivan RF, Ferrari G, Mignatti P, Galloway AC. Mechanisms of C-reactive protein upregulation in arterialized vein grafts. Surgery 2006, 139: 254-262.
58. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, Galloway AC, Mignatti P. Matrix Metalloproteinase Expression in Vein Grafts: The Role of Inflammatory Mediators and Extracellular Signal-Regulated Kinases -1 and -2. American Journal of Physiology 2006, p290p: H1651 - H1659 (appeared online Nov 11, 2005, doi:10.1152/ajpheart.00530.2005).
59.pPintucci G, Saunders PC, Gulkarov I, Bohmann K, Kadian-Dodov DL, Baumann, Galloway AG, Mignatti P. Inhibition of ERK-1/2 activation in arterialized vein grafts: effect on cell proliferation, apoptosis and inflammation. FASEB Journal 2006, 20: 398-400 (appeared online Nov 22, 2005, doi:10.1096/fj.05-4114fje).
60. Ferrari G, Pintucci G, Seghezzi G, Hyman K, Galloway AC, Mignatti P.Vascular Endothelial Growth Factor (VEGF), a Pro-Survival Factor, Acts in Concert With Transforming Growth Factor-Beta 1 (TGF-b1) to Induce Endothelial Cell Apoptosis. Proceedings of the National Academy of Sciences USA 2006, 103: 17260–17265 (published online Nov 6, 2006, doi:10.1073/pnas.0605556103).
61. D’Alessio S, Ferrari G, Cinnante K, Scheerer WJ, Rozanov DV, Strongin A, Galloway AC, Pintucci G, Mignatti P. TIMP-2 – MT1-MMP binding induces MAP kinase activation and cell growth by a non-proteolytic mechanism. The Journal of Biological Chemistry, under review (July 07).
62. Yu PJ, Ferrari G, Pirelli L, Galloway AC, Mignatti P, Pintucci G. Thrombin Cleaves High-Molecular Weight Basic Fibroblast Growth Factor-2 (FGF-2): a Novel Mechanism for the Control of FGF-2 and Thrombin Activity. Oncogene, under review (July 07).
Review
1. Mignatti P, Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiological Reviews 1993; 73: 161-195.
2. Mignatti P. The fibrinolytic system and angiogenesis. Fibrinolysis 1993; 7: 20-21.
3. Mignatti P. Extracellular matrix remodeling by metalloproteinases and plasminogen activatorsKidney International 1995;49: 12-14.
4. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. In: Ossowski L, Mira y Lopez R, eds. Enzyme & Protein, Proteolytic Enzymes in Cancer Invasion. Basel: Karger, Basel, 1996; 49: 117-137.
5. Mignatti P, Rifkin D.B. Plasminogen activators and angiogenesis. InGünthert U, Birchmeier W, eds Current Topics in Microbiology and Immunology, Attempts to Understand Metastasis Formation, vol. I. Heidelberg: Springer Verlag, 1996: 33-50.
6. Mignatti P, Rifkin DB. Non-enzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Advances in Cancer Research 2000, 78: 103-157.
7. Pirelli L, Yu P-J, Gulkarov I, Galloway AC, Mignatti P, Pintucci G. Inhibition of mitogen-activated protein kinases (MAPKs) as a strategy to prevent intimal hyperplasia following cardiovascular interventions. Vascular Disease Prevention 2006, 3: 173-183.
8. Yu PJ, Ferrari G, Galloway AC, Mignatti P, Pintucci G. Basic fibroblast growth factor (FGF-2): the high molecular weight forms come of age. Journal of Cellular Biochemistry. Published online 27 Nov. 2006.
9. Yu P-J, Ferrari G, Pirelli L, Gulkarov I, Galloway AC, Mignatti P, Pintucci G. Vascular Injury and Modulation of MAPKs: A Targeted Approach to Therapy of Restenosis. Cell Signal, In Press
Book Chapters
1. Barlati S, Mignatti P, Brega A, De Petro G, Ascari E. Utilization of Rous sarcoma virus for the detection of transformation-enhancing and inhibiting factors in human plasma. In: Barlati S, De Giuli-Morghen, eds. Avian RNA Tumor Viruses. Padoua: Piccin Medical Books, 1978: 331-348.
2. Barlati S, Mignatti P. Transformation-enhancing factors in the plasma of cancer patients. In: Jimenez de Asua R., Levi-Montalcini R, et al, eds. Control Mechanisms in Animal Cells. New York: Raven Press, 1980: 269-277.
3. Barlati S, Mignatti P, Zanada G, Boiocchi M. Induction of transformation-enhancing activities in the plasma of mice injected with tumorigenic cells. In: Galeotti T, et al, eds. Membranes in Tumor Growth. Amsterdam: Elsevier Biomedical Press, 1982: 255-260.
4.Mignatti P, Barlati S, Pouillart P, Zucker JM, Crochet J, Vigier P. Prevalence of transformation-enhancing activity in the plasma of cancer patients. In: Peeters H, ed. Protides of the Biological Fluids. Oxford and New York: Pergamon Press, 1983: 275-280.
5.Rohrlich ST, Siegfried Z, Mignatti P, Machleidt W, Levy H, Rifkin DB. Characterization of low molecular mass cysteine proteinase inhibitors from human amniotic fluid. In: Turk V, ed. Cysteine Proteinases and Their Inhibitors. Berlin-New York: W. de Gruyter & Co., 1986: 455-471.
6. Levy H, Mignatti P, Rifkin DB. Characterization of a collagenase inhibitor from human amniotic fluid, which inhibits tumor cell invasion. In: Tschesche H, ed. Proteinases in Inflammation and Tumor Invasion. Berlin-New York: W. de Gruyter & Co., 1986: 321-335.
7. Rifkin DB, Saksela O, Moscatelli D, Presta M, Mignatti P, Ossowski L. Studies on the regulation of protease activity during cell invasion and angiogenesis. In: Rifkin DB, Klagsbrun M, eds. Angiogenesis. Mechanisms and Pathobiology. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1987: 1120-113.
8. Mignatti P, Welgus HG, Rifkin DB. Role of degradative enzymes in wound healing. In: Clark RAF, Henson P, eds. The Molecular and Cellular Biology of Wound Repair. New York: Plenum Publishing Co., 1988: 497-523.
9. Mignatti P, Fognani C, Tredici F, Negri M, Della Valle G, De Carli L. Expression of alkaline phosphatase in human cell lines is regulated at both transcriptional and post-transcriptional level. In: Bissel, Dehò, Sironi, Torriani, eds. Excerpta Medica, Gene Expression and Regulation: The Legacy of Luigi Gorini., Elsevier Science Publishers, 1988: 353-362.
10. Mignatti P, Rifkin DB, Welgus HG, Parks WC. Proteinases and tissue remodeling. In: Clark RAF, Henson P, eds. The Molecular and Cellular Biology of Wound Repair. Second Edition. New York: Plenum Publishing Co., 1996: 427-474.